Novo Nordisk, leader in diabetes care, will launch in Lebanon its new generation basal insulin -Insulin Degludec- in an event to be held on 10th April 2014 at La Magnanerie.
A 3D Video Mapping Show will be created for this occasion. The idea behind the movie is to show the history and development through the years of Novo Nordisk diabetes portfolio leading to the launch of its latest insulin molecule that will be marketed in a new device under the name of Tresiba® FlexTouch®
Novo Nordisk is a global healthcare company with 90 years of innovation. In addition to diabetes, the company has also leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees with offices in more than 76 countries, and markets its products in more than 180 countries!